Minerva Neurosciences, Inc. (NERV) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 5 Buy, 2 Hold.
The consensus price target is $5.00, representing a downside of 19.1% from the current price $6.18.
Analysts estimate Earnings Per Share (EPS) of $-0.30 and revenue of $0.02B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $0.19 vs est $-0.30 (beat +163.3%). 2025: actual $-34.67 vs est $-1.59 (missed -2078.2%). Analyst accuracy: 0%.
NERV Stock — 12-Month Price Forecast
$5.00
▼ -19.09% Downside
Average Price Target
Based on 7 Wall Street analysts offering 12-month price targets for Minerva Neurosciences, Inc., the price target is $5.00.
The average price target represents a -19.09% change from the last price of $6.18.
NERV Analyst Ratings
Buy
Based on 7 analysts giving stock ratings to Minerva Neurosciences, Inc. in the past 3 months
EPS Estimates — NERV
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.19
vs Est –$0.30
▲ 257.9% off
2025
Actual –$34.67
vs Est –$1.59
▼ 95.4% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. Analysts expect losses to continue near-term.
Revenue Estimates — NERV
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
